SI1912640T1 - Uporaba inhibitorja hdac panobinostata za zdravljenje mieloma - Google Patents

Uporaba inhibitorja hdac panobinostata za zdravljenje mieloma

Info

Publication number
SI1912640T1
SI1912640T1 SI200631952T SI200631952T SI1912640T1 SI 1912640 T1 SI1912640 T1 SI 1912640T1 SI 200631952 T SI200631952 T SI 200631952T SI 200631952 T SI200631952 T SI 200631952T SI 1912640 T1 SI1912640 T1 SI 1912640T1
Authority
SI
Slovenia
Prior art keywords
myeloma
treatment
hdac inhibitor
inhibitor panobinostat
panobinostat
Prior art date
Application number
SI200631952T
Other languages
English (en)
Inventor
Peter W. Atadja
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37307336&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1912640(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI1912640T1 publication Critical patent/SI1912640T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200631952T 2005-08-03 2006-08-01 Uporaba inhibitorja hdac panobinostata za zdravljenje mieloma SI1912640T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70522605P 2005-08-03 2005-08-03
EP06789025.1A EP1912640B1 (en) 2005-08-03 2006-08-01 Use of the hdac inhibitor panobinostat for the treatment of myeloma
PCT/US2006/029801 WO2007019116A1 (en) 2005-08-03 2006-08-01 Use of hdac inhibitors for the treatment of myeloma

Publications (1)

Publication Number Publication Date
SI1912640T1 true SI1912640T1 (sl) 2015-10-30

Family

ID=37307336

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200631952T SI1912640T1 (sl) 2005-08-03 2006-08-01 Uporaba inhibitorja hdac panobinostata za zdravljenje mieloma

Country Status (18)

Country Link
US (2) US20080221126A1 (sl)
EP (1) EP1912640B1 (sl)
JP (2) JP5665271B2 (sl)
KR (1) KR101354237B1 (sl)
CN (2) CN101232880A (sl)
AU (1) AU2006278718B2 (sl)
BR (1) BRPI0614090A2 (sl)
CA (1) CA2617274C (sl)
DK (1) DK1912640T3 (sl)
ES (1) ES2545076T3 (sl)
HU (1) HUE028025T2 (sl)
LT (1) LTC1912640I2 (sl)
MX (1) MX2008001610A (sl)
PL (1) PL1912640T3 (sl)
PT (1) PT1912640E (sl)
RU (1) RU2420279C3 (sl)
SI (1) SI1912640T1 (sl)
WO (1) WO2007019116A1 (sl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1912640B1 (en) * 2005-08-03 2015-06-17 Novartis AG Use of the hdac inhibitor panobinostat for the treatment of myeloma
KR20090110913A (ko) * 2007-02-15 2009-10-23 노파르티스 아게 Ｌｂｈ589와 암을 치료하기 위한 다른 치료제와의 조합물
EP2162129B1 (en) * 2007-05-30 2019-03-06 Novartis AG Use of hdac inhibitors for the treatment of bone destruction
US20120046242A1 (en) * 2008-12-24 2012-02-23 Massachusetts Institute Of Technology Molecular activators of the wnt/beta-catenin pathway
RS61829B1 (sr) † 2009-11-13 2021-06-30 Receptos Llc Selektivni modulatori receptora sfingozin 1 fosfata i metode hiralne sinteze
CN104399081A (zh) * 2010-09-01 2015-03-11 诺华有限公司 Hdac抑制剂与血小板减少症药物的组合
MA41544A (fr) * 2015-02-19 2017-12-26 Novartis Ag Dosages de panobinostat pour le traitement du myélome multiple
WO2017077008A1 (en) 2015-11-03 2017-05-11 Hochschule Darmstadt Selective hdac8 inhibitors and their uses
CN105348169B (zh) * 2015-11-16 2018-03-30 青岛大学 一种组蛋白去乙酰酶抑制剂(e)‑3‑(2‑(1‑(4‑氯苯甲酰基)‑5‑甲氧基‑2‑甲基‑1氢‑吲哚‑3‑基)乙酰氨基)‑n‑羟基丁‑2‑烯酰胺及其制备方法和应用
CN109705057B (zh) * 2017-10-25 2023-05-30 成都先导药物开发股份有限公司 组蛋白去乙酰化酶抑制剂及其制备方法与用途
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
EP3823589A1 (en) 2018-07-18 2021-05-26 Hillstream Biopharma Inc. Polymeric nanoparticles comprising salinomycin
WO2022251844A1 (en) 2021-05-25 2022-12-01 Hillstream Biopharma, Inc. Polymeric nanoparticles comprising chemotherapeutic compounds and related methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
KR20030094415A (ko) * 2001-05-16 2003-12-11 노파르티스 아게 Ν-｛5-[4-(4-메틸-피페라지노-메틸)-벤조일아미도]-2-메틸페닐｝-4-(3-피리딜)-2-피리미딘-아민 및 화학치료제를포함하는 배합물
US20050227300A1 (en) * 2001-12-07 2005-10-13 Atadja Peter W Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20070123580A1 (en) * 2003-05-21 2007-05-31 Atadja Peter W Combination of histone deacetylase inhibitors with chemotherapeutic agents
CA2535889A1 (en) 2003-08-29 2005-03-17 Aton Pharma, Inc. Combination methods of treating cancer
JP5744376B2 (ja) 2005-03-22 2015-07-08 プレジデント アンド フェローズ オブ ハーバード カレッジ タンパク質分解障害の治療
EP1912640B1 (en) * 2005-08-03 2015-06-17 Novartis AG Use of the hdac inhibitor panobinostat for the treatment of myeloma

Also Published As

Publication number Publication date
JP2009503087A (ja) 2009-01-29
CN104324025A (zh) 2015-02-04
LTC1912640I2 (lt) 2017-09-11
US8883842B2 (en) 2014-11-11
AU2006278718A1 (en) 2007-02-15
CA2617274C (en) 2017-10-10
PT1912640E (pt) 2015-09-22
MX2008001610A (es) 2008-02-19
KR20080031937A (ko) 2008-04-11
AU2006278718B2 (en) 2010-10-07
BRPI0614090A2 (pt) 2011-03-09
PL1912640T3 (pl) 2015-11-30
JP5876435B2 (ja) 2016-03-02
WO2007019116A1 (en) 2007-02-15
DK1912640T3 (en) 2015-09-14
JP2013173757A (ja) 2013-09-05
EP1912640B1 (en) 2015-06-17
US20080221126A1 (en) 2008-09-11
JP5665271B2 (ja) 2015-02-04
US20100160257A1 (en) 2010-06-24
RU2008107871A (ru) 2009-09-10
RU2420279C2 (ru) 2011-06-10
RU2420279C3 (ru) 2017-03-14
EP1912640A1 (en) 2008-04-23
HUE028025T2 (en) 2016-11-28
CA2617274A1 (en) 2007-02-15
KR101354237B1 (ko) 2014-01-22
CN101232880A (zh) 2008-07-30
ES2545076T3 (es) 2015-09-08

Similar Documents

Publication Publication Date Title
SI1912640T1 (sl) Uporaba inhibitorja hdac panobinostata za zdravljenje mieloma
AP2870A (en) Odcase inhibitors for the treatment of malaria
IL183938A0 (en) Amino - imidazolones for the inhibition of ?? - becretase
ZA200801394B (en) Novel sulphonylpyrroles as inhibitors of HDAC S novel sulphonylpyrroles
HRP20130810T1 (en) Sulphonylpyrroles as hdac inhibitors
LT2295410T (lt) Hdac inhibitorius
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en) PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
EP1898834A4 (en) SELF-ADJUSTABLE ENDO-URETRAL DEVICE AND METHODS OF USE
IL189659A0 (en) Ikk inhibitors for the treatment of endometriosis
EP2049505A4 (en) ISOFORM SELECTIVE HDAC HEMMER
EP1965824A4 (en) METABOLITENE DERIVATIVES OF HDAC INHIBITOR FK228
PT2056814E (pt) Compostos de 2,5-di-hidroxibenzeno para o tratamento da psoríase
EP1888056A4 (en) USE OF LADOSTIGIL FOR TREATING MULTIPLE SCLEROSIS
GB0624187D0 (en) HDAC inhibitors
ZA201100165B (en) Use of hdac inhibitors for the treatment of hodgkin's disease
GB0515035D0 (en) Treatment of atherosclerotic conditions
IL201466A0 (en) Use of hdac inhibitors for the treatment of bone destruction
PT1962913E (pt) Radioimunoconjugado para cd66 humano para o tratamento de mieloma múltiplo
GB0602857D0 (en) The treatment of sialorrhoea
IL201439A0 (en) Use of hdac inhibitors for the treatment of melanoma
ZA200906906B (en) Use of HDAC inhibitors for the treatment of melanoma
EE200800070A (et) HDAC inhibiitorite kasutamine lmfoomide raviks
GB0621474D0 (en) Composition for the treatment of halitosis
ZA200801707B (en) IKK inhibitors for the treatment of endometriosis